Concepedia

Amir Tavakkol

AT

Statistics

Publications

20

Citations

862

H-Index

16

Active since

1983

Affiliations

Novartis (United States)(Current)

University of Alabama at Birmingham

Novartis (Switzerland)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Clinical Trials of Texas

Amir Tavakkol is an author at Novartis (United States) specializing in dermatology, pharmacology, and medicine.

Publications per year

1983–2022

20

Publications

20

Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials∗

Boni E. Elewski, Héctor Cáceres, Liberation DeLeon et al. · Journal of the American Academy of Dermatology · 2008 · 126 citations

, , +4

Treatment of Chronic Rhinosinusitis with High-Dose Oral Terbinafine: A Double Blind, Placebo-Controlled Study

David W. Kennedy, F KUHN, Daniel L. Hamilos et al. · The Laryngoscope · 2005 · 123 citations

, , +15

Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Boni E. Elewski, Amir Tavakkol · PubMed · 2005 · 87 citations

, , +17

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

Boni E. Elewski, Richard Pollak, S. Ashton et al. · British Journal of Dermatology · 2011 · 63 citations

, , +17

Treatment of Toenail Onychomycosis with Oral Terbinafine Plus Aggressive Debridement

Maureen Jennings, Richard Pollak, Lawrence B. Harkless et al. · Journal of the American Podiatric Medical Association · 2006 · 46 citations

, , +15

1–5 of 20